Tutuncu Nb

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3265263/publications.pdf

Version: 2024-02-01

122 papers	7,563 citations	136740 32 h-index	53109 85 g-index
128 all docs	128 docs citations	128 times ranked	8571 citing authors

#	Article	IF	Citations
1	A Case Report of Conversion from Hashimotoâ€™s Thyroiditis to Gravesâ€™ Disease in Type 1 Diabetic Patient Following the COVID-19 Vaccination. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2023, 23, 405-409.	0.6	4
2	A Case Report of Concurrent Gravesâ€™ Disease and Subacute Thyroiditis Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome (ASIA). Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, .	0.6	4
3	Acoustic Radiation Force Impulse Elastography and Ultrasonographic Findings of Achilles Tendon in Patients With and Without Diabetic Peripheral Neuropathy: A Cross-Sectional Study. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 99-103.	0.6	10
4	Patterns and preferences of antidiabetic drug use in Turkish patients with type 2 diabetes â€“ A nationwide cross-sectional study (TEMD treatment study). Diabetes Research and Clinical Practice, 2021, 171, 108556.	1.1	6
5	Characteristics of patients with hypertension in a population with type 2 diabetes mellitus. Results from the Turkish Nationwide SurvEy of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Hypertension Study). Primary Care Diabetes, 2021, 15, 332-339.	0.9	13
6	Severe chronic periodontitis is not common in Acromegaly: Potential protective role of gingival BMP-2. Turkish Journal of Medical Sciences, 2021, 51, 1172-1178.	0.4	3
7	Risk Factors and Treatment Options for Persistent Hyperparathyroidism After Kidney Transplantation. Transplantation Proceedings, 2020, 52, 157-161.	0.3	7
8	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. Cardiovascular Diabetology, 2020, 19, 175.	2.7	1
9	Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study). Lipids in Health and Disease, 2020, 19, 237.	1.2	8
10	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. European Journal of Heart Failure, 2020, 22, 1133-1143.	2.9	16
11	The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma. Turkish Journal of Medical Sciences, 2020, 50, 870-876.	0.4	7
12	A Cross-Sectional Study of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Diabetes Mellitus: The TEMD Overtreatment Study. Diabetes Therapy, 2020, 11, 1045-1059.	1.2	14
13	Short-Term Effect of Hypergastrinemia Following Esomeprazole Treatment On Well-Controlled Type 2 Diabetes Mellitus: A Prospective Study. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 1090-1096.	0.6	2
14	Turkish Society of Cardiology Consensus Paper on Evaluation and Treatment of Resistant Hypertension. Anatolian Journal of Cardiology, 2020, 24, 137-152.	0.5	2
15	Preventive and therapeutic effects of relaxin on bisphosphonaterelated osteonecrosis of the jaw: an experimental study in rats. Brazilian Dental Science, 2020, 23, .	0.1	0
16	Uncoupling protein gene ucp1-3826a/g, ucp2 ins/del and ucp3-55c/t polymorphisms in obese turkish children. Turkish Journal of Pediatrics, 2020, 62, 921.	0.3	3
17	The curative treatment of familial hypercholesterolemia: Liver transplantation. Clinical Transplantation, 2019, 33, e13730.	0.8	10
18	Impact of Obesity on the Metabolic Control of Type 2 Diabetes: Results of the Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Obesity) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	38

#	Article	IF	Citations
19	Thyroid Nodules Are More Prevalent in Subjects with Colon Polyps, Independent of Insulin Resistance. Medical Principles and Practice, 2019, 28, 418-424.	1.1	2
20	Effects of basal insulin glargine and omegaâ€3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial. Diabetes, Obesity and Metabolism, 2019, 21, 1502-1505.	2.2	3
21	The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a realâ€world setting. Diabetes, Obesity and Metabolism, 2019, 21, 1429-1436.	2.2	28
22	The association of basal insulin treatment versus standard care with outcomes in antiâ€GAD positive and negative subjects: A postâ€hoc analysis of the ORIGIN trial. Diabetes, Obesity and Metabolism, 2019, 21, 429-433.	2.2	5
23	Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial. European Journal of Preventive Cardiology, 2019, 26, 847-854.	0.8	11
24	Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial. Diabetes Care, 2019, 42, 142-147.	4.3	18
25	Abdominal Bioelectric Impedance for Follow-Up of Dieters: a Prospective Study. Acta Endocrinologica, 2019, 15, 145-152.	0.1	2
26	An international survey on hypoglycemia among insulin-treated type I and type II diabetes patients: Turkey cohort of the non-interventional IO HAT study. BMC Endocrine Disorders, 2018, 18, 9.	0.9	5
27	Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study. Medical Principles and Practice, 2018, 27, 1-7.	1.1	12
28	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization. Circulation, 2018, 137, 88-90.	1.6	30
29	Insulin resistance and cardiovascular outcomes in the <scp>ORIGIN</scp> trial. Diabetes, Obesity and Metabolism, 2018, 20, 564-570.	2.2	10
30	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. Journal of Diabetes Research, 2018, 2018, 1-9.	1.0	26
31	Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study). Diabetes Research and Clinical Practice, 2018, 146, 138-147.	1.1	25
32	Comments on Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The Origin Study. American Journal of Medicine, 2018, 131, e315.	0.6	0
33	Fat Distribution and Metabolic Profile in Subjects with Hashimotoâ€™s Thyroiditis. Acta Endocrinologica, 2018, 14, 105-112.	0.1	9
34	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. American Journal of Medicine, 2017, 130, 1465.e27-1465.e39.	0.6	17
35	Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. Diabetes Research and Clinical Practice, 2017, 132, 137-143.	1.1	0
36	Comment on â€œMetformin Decreases Thyroid Volume and Nodule Size in Subjects with Insulin Resistance: A Preliminary Studyâ€• Medical Principles and Practice, 2017, 26, 199-200.	1.1	0

#	Article	IF	Citations
37	Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic People. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2251-2257.	1.8	13
38	Serum Adiponectin Level as a Predictor of Subclinical Cushingâ€™s Syndrome in Patients with Adrenal Incidentaloma. International Journal of Endocrinology, 2016, 2016, 1-8.	0.6	9
39	Metformin Decreases Thyroid Volume and Nodule Size in Subjects with Insulin Resistance: A Preliminary Study. Medical Principles and Practice, 2016, 25, 233-236.	1.1	38
40	Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. Diabetes Therapy, 2016, 7, 187-201.	1.2	29
41	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care, 2016, 39, 709-716.	4.3	55
42	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 2015, 169, 631-638.e7.	1.2	88
43	Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial. Diabetes Care, 2015, 38, 22-28.	4.3	64
44	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine, 2015, 373, 2247-2257.	13.9	1,856
45	Low Prevalence of Periodontitis in Acromegaly: Growth Hormone May Exert a Protective Effect. Turkish Journal of Endocrinology and Metabolism, 2015, 19, 42-48.	0.5	4
46	Insulin Resistance in Non-Obese Polycystic Ovary Syndrome Subjects and Relation with Family History of Diabetes Mellitus. Turkish Journal of Endocrinology and Metabolism, 2015, 19, 55-59.	0.5	2
47	Thyroid volume in patients with glucose metabolism disorders. Arquivos Brasileiros De Endocrinologia E Metabologia, 2014, 58, 824-827.	1.3	21
48	Acromegaly is protective for periodontal tissue â€“ advanced chronic periodontitis is rare in acromegalics. Bratislava Medical Journal, 2014, 115, 588-592.	0.4	4
49	Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia, 2014, 57, 1325-1331.	2.9	47
50	The relationship between thyroid volume and malignant thyroid disease. Medical Oncology, 2014, 31, 814.	1.2	11
51	Is the incidence of temporomandibular disorder increased in polycystic ovary syndrome?. British Journal of Oral and Maxillofacial Surgery, 2014, 52, 822-826.	0.4	10
52	The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care, 2014, 37, 1360-1366.	4.3	76
53	Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: A subanalysis of the ORIGIN trial. International Journal of Cardiology, 2014, 174, 458-461.	0.8	83
54	The relationship between glucose metabolism disorders and malignant thyroid disease. International Journal of Clinical Oncology, 2013, 18, 585-589.	1.0	9

#	Article	IF	Citations
55	Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. European Heart Journal, 2013, 34, 3137-3144.	1.0	211
56	Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915-2922. Diabetes Care, 2013, 36, e181-e181.	4.3	1
57	Successful Management of a Giant Pituitary Lactosomatotroph Adenoma Only with Cabergoline. Case Reports in Endocrinology, 2013, 2013, 1-4.	0.2	2
58	Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care, 2013, 36, 2915-2922.	4.3	26
59	Performance of Abdominal Bioelectrical Impedance Analysis and Comparison with Other Known Parameters in Predicting the Metabolic Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2013, 121, 391-396.	0.6	5
60	Sepsiste Steroid KullanÄ±mÄ±. Turkish Journal of Endocrinology and Metabolism, 2013, 17, 121-124.	0.5	0
61	Tiroid Kanserinde Tirozin Kinaz Ä°nhibitÃ¶rleri: Axl/Gas6 YolaÄŸÄ± Gizli Bir Hedef Olabilir mi?. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2013, 23, 207-212.	0.1	0
62	Insulin Glargine in Gastrostomy Feeding. Acta Endocrinologica, 2012, 8, 257-263.	0.1	0
63	nâ€“3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine, 2012, 367, 309-318.	13.9	810
64	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	13.9	1,426
65	Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma. Medical Oncology, 2012, 29, 294-300.	1.2	19
66	Macroprolactinemia, like hyperprolactinemia, may promote platelet activation. Endocrine, 2010, 37, 294-300.	1.1	13
67	Rapidly Progressing Malignant Insulinoma Presented with Multiple Liver Metastases: A Case Report. Journal of Gastrointestinal Cancer, 2010, 41, 272-274.	0.6	1
68	The 5-Year Incidence of Type 2 Diabetes Mellitus in Women Older Than 15 Years in Ankara, Turkey. Journal of Investigative Medicine, 2010, 58, 796-800.	0.7	0
69	Newly diagnosed hyperglycemia and stress hyperglycemia in a coronary intensive care unit. Diabetes Research and Clinical Practice, 2010, 90, 8-14.	1.1	17
70	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet, The, 2010, 376, 517-523.	6.3	222
71	The 5-year incidence of type 2 diabetes mellitus in women older than 15 years in Ankara, Turkey: a population-based study. Journal of Investigative Medicine, 2010, 58, 796-800.	0.7	0
72	49,XXXXY Syndrome with Autoimmune Diabetes and Ocular Manifestations. Medical Principles and Practice, 2009, 18, 482-485.	1.1	12

#	Article	IF	Citations
73	Unresectable Huge Sternal and Mediastinal Metastasis of Follicular Thyroid Carcinoma; Radiotherapy as First-line and Palliative Therapy. Experimental and Clinical Endocrinology and Diabetes, 2009, 117, 155-158.	0.6	6
74	Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area. European Journal of Endocrinology, 2009, 161, 599-605.	1.9	167
75	Prevalence of osteoporosis and factors affecting bone mineral density among postmenopausal Turkish women with type 2 diabetes. Journal of Diabetes and Its Complications, 2009, 23, 12-17.	1.2	52
76	Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetologica, 2009, 46, 63-65.	1.2	33
77	Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. Clinical Endocrinology, 2009, 70, 469-474.	1.2	174
78	Systolic pulmonary artery pressure and echocardiographic measurements in patients with euthyroid Hashimotoâ€™s thyroiditis. Journal of Endocrinological Investigation, 2009, 32, 530-532.	1.8	12
79	Clinical and epidemiological characteristics of thyroid hemiagenesis: ultrasound screening in patients with thyroid disease and normal population. Endocrine, 2008, 33, 338-341.	1.1	42
80	Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial*. Diabetes, Obesity and Metabolism, 2008, 10, 387-399.	2.2	60
81	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial) Tj ETQq1 1 0.784314 rgBT /Over	3.1	37
82	Clinicopathological Characteristics of Thyroid Cancer in Patients on Dialysis for End-Stage Renal Disease. Thyroid, 2008, 18, 45-50.	2.4	8
83	Subclinical Hypothyroidism Is Characterized by Increased QT Interval Dispersion among Women. Medical Principles and Practice, 2008, 17, 390-394.	1.1	40
84	Evaluation of Brain Natriuretic Peptide Levels in Hyperthyroidism and Hypothyroidism. Journal of the National Medical Association, 2008, 100, 401-405.	0.6	27
85	Radioactive Iodine in the Treatment of Type-2 Amiodarone-Induced Thyrotoxicosis. Journal of the National Medical Association, 2008, 100, 716-720.	0.6	14
86	The biodistribution of radioiodine on posttherapy iodine-131 scans in thyroid cancer patients with chronic renal failure. Nuclear Medicine Communications, 2008, 29, 943-948.	0.5	5
87	Needle-Free Delivery of Lidocaine for Reducing the Pain Associated with the Fine-Needle Aspiration Biopsy of Thyroid Nodules: Time-Saving and Efficacious Procedure. Thyroid, 2007, 17, 317-321.	2.4	29
88	Rosiglitazone Decreases Serum Bone-Specific Alkaline Phosphatase Activity in Postmenopausal Diabetic Women. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3523-3530.	1.8	103
89	Serum Osteoprotegerin Concentration with Strontium Ranelate Treatment for Postmenopausal Osteoporosis: An Open, Prospective Study. Current Therapeutic Research, 2007, 68, 217-225.	0.5	0
90	The analgesic efficacy of lidocaine/prilocaine (EMLA) cream during fine-needle aspiration biopsy of thyroid nodules. Clinical Endocrinology, 2007, 66, 691-694.	1.2	32

#	Article	IF	Citations
91	The effect of single-dose orlistat on postprandial serum glucose, insulin and glucagon-like peptide-1 levels in nondiabetic obese patients. Clinical Endocrinology, 2007, 67, 346-350.	1.2	14
92	Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2007, 21, 118-123.	1.2	116
93	Mean platelet volume in patients with polycystic ovary disease. Platelets, 2006, 17, 505-506.	1.1	11
94	Changes in Insulin Sensitivity and Glucose and Bone Metabolism over Time in Patients with Asymptomatic Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4260-4263.	1.8	43
95	Polycythemia as the first manifestation of Cushingâ€™s disease. Journal of Endocrinological Investigation, 2006, 29, 742-744.	1.8	26
96	Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules. Clinical Endocrinology, 2006, 65, 514-518.	1.2	80
97	Ultrasound-Guided Fine-Needle Aspiration Biopsy and Ultrasonographic Features of Infracentimetric Nodules in Patients with Nodular Goiter: Correlation with Pathological Findings. Endocrine Pathology, 2006, 17, 67-74.	5.2	25
98	Familial dilated cardiomyopathy hypergonadotrophic hypogonadism associated with thyroid hemiagenesis. American Journal of Medical Genetics, Part A, 2006, 140A, 895-896.	0.7	9
99	Effects of raloxifene on platelet functions in patients with postmenopausal osteoporosis. Platelets, 2006, 17, 351-353.	1.1	2
100	Thermolabile methylenetetrahydrofolate reductase enzyme genotype is frequent in type 2 diabetic patients with normal fasting homocysteine levels. Journal of Internal Medicine, 2005, 257, 446-453.	2.7	16
101	Melatonin levels decrease in type 2 diabetic patients with cardiac autonomic neuropathy. Journal of Pineal Research, 2005, 39, 43-49.	3.4	76
102	Thyroid cancer in hyperthyroidism: Incidence rates and value of ultrasound-guided fine-needle aspiration biopsy in this patient group. Journal of Endocrinological Investigation, 2005, 28, 815-818.	1.8	26
103	Factors Associated with Bone Metabolism in Acromegalic Patients: Hypogonadism and Female Gender. Experimental and Clinical Endocrinology and Diabetes, 2004, 112, 328-332.	0.6	15
104	Prolonged P300 Latency in Thyroid Failure: A Paradox. P300 Latency Recovers Later in Mild Hypothyroidism Than in Severe Hypothyroidism. Thyroid, 2004, 14, 622-627.	2.4	13
105	Autoimmune Hypoglycemia in a Type 2 Diabetic Patient With Anti-Insulin and Insulin Receptor Antibodies: Response to Kim et al.. Diabetes Care, 2004, 27, 1246-1247.	4.3	24
106	Influence of 1,25-dihydroxyvitamin D3 as an immunomodulator in renal transplant recipients: a retrospective cohort study. Transplantation Proceedings, 2003, 35, 2885-2887.	0.3	42
107	Alveolar Gas Exchange in Patients with Type 2 Diabetes Mellitus. Endocrine Journal, 2003, 50, 663-667.	0.7	36
108	Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes, Obesity and Metabolism, 2002, 4, 49-55.	2.2	137

#	Article	IF	Citations
109	Effects of Sibutramine in Obese Female Subjects With Type 2 Diabetes and Poor Blood Glucose Control. Diabetes Care, 2001, 24, 1957-1960.	4.3	99
110	Unusual Case of Metastatic Thyroid Nodule: Nonpalpable Breast Mass as Origin. Endocrine Practice, 2001, 7, 379-382.	1.1	5
111	Chlamydia Pneumonia Seropositivity Correlates with Serum Fibrinogen and Lipoprotein a Levels: Any Role in Atherosclerosis?. Endocrine Journal, 2001, 48, 269-274.	0.7	8
112	Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetologica, 2001, 38, 157-161.	1.2	49
113	Major Determinants of the Carotid Intima-Media Thickness in Type 2 Diabetic Patients. Age and Body Mass Index.. Endocrine Journal, 2000, 47, 525-533.	0.7	23
114	Quantitative CT of the orbit in Graves' disease.. British Journal of Radiology, 1999, 72, 757-762.	1.0	36
115	Adrenal incidentaloma: Report of 33 cases. , 1999, 70, 247-250.		20
116	Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study. Diabetes Care, 1998, 21, 1915-1918.	4.3	88
117	Breathlessness in a patient with rheumatoid vasculitis.. Postgraduate Medical Journal, 1998, 74, 294-297.	0.9	0
118	Ifosfamide-based Chemotherapy for Recurrent or Metastatic Hemangiopericytoma. Acta OncolÃ³gica, 1997, 36, 348-348.	0.8	8
119	Primary central nervous system lymphoma presenting with multiple myeloma-like clinical picture. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 63, 409-410.	0.9	1
120	Evisceration of the Eye in a Renal Transplant Recipient with Cytomegalovirus Chorioretinitis. American Journal of Nephrology, 1996, 16, 367-368.	1.4	0
121	Difficult Diagnosis in a Patient with Multiple Osteoblastic Thoracic Vertebral Lesions. Annals of Saudi Medicine, 1996, 16, 590-590.	0.5	0
122	Acoustic Radiation Force Impulse Elastography and Ultrasonographic Findings of Achilles Tendon in Patients with and without diabetic peripheral neuropathy: a cross-sectional study. Endocrine Abstracts, 0, , .	0.0	1